Ocular Therapeutix Inc. [OCUL] Stock sold by Insider Ozden Rabia Gurses for $4102.0


In a filing, Ocular Therapeutix Inc. revealed its Chief Medical Officer Ozden Rabia Gurses unloaded Company’s shares for reported $4102.0 on Jul 07. In the deal valued at $4.93 per share,832 shares were sold. As a result of this transaction, Ozden Rabia Gurses now holds 100,531 shares worth roughly $ 0.39 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Mattessich Antony C. sold 19,669 shares, generating $83,397 in total proceeds. Upon selling the shares at $4.24, the President and CEO now owns 446,281 shares.

Before that, Notman Donald sold 6,476 shares. Ocular Therapeutix Inc. shares valued at $27,458 were divested by the Chief Financial Officer at a price of $4.24 per share. As a result of the transaction, Notman Donald now holds 139,387 shares, worth roughly $0.54 million.

Robert W. Baird initiated its Ocular Therapeutix Inc. [OCUL] rating to an Outperform in a research note published on Friday, April 21, 2023; the price target was $18. PT values the company’s stock at a premium of 78.39 to its Friday closing price.

Price Performance Review of OCUL

On Friday, Ocular Therapeutix Inc. [NASDAQ:OCUL] saw its stock jump 3.46% to $3.89. On the same session, the stock had its day’s lowest price of $3.715, but rose to a high of $3.935. Over the last five days, the stock has lost -7.38%. Ocular Therapeutix Inc. shares have risen nearly 38.43% since the year began. Nevertheless, the stocks have fallen -28.36% over the past one year. While a 52-week high of $7.96 was reached on 06/12/23, a 52-week low of $2.57 was recorded on 01/03/23. SMA at 50 days reached $4.53, while 200 days put it at $4.71. A total of 0.61 million shares were traded, compared to the trading of 0.71 million shares in the previous session.

Levels Of Support And Resistance For OCUL Stock

The 24-hour chart illustrates a support level at 3.76, which if violated will result in even more drops to 3.63. On the upside, there is a resistance level at 3.98. A further resistance level may holdings at 4.07. The Relative Strength Index (RSI) on the 14-day chart is 38.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.26, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.44%. Stochastics %K at 19.26% indicates the stock is a buying.

How much short interest is there in Ocular Therapeutix Inc.?

A steep rise in short interest was recorded in Ocular Therapeutix Inc. stocks on Aug 14, 2023, dropping by -1.8 million shares to a total of 4.92 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 6.72 million shares. There was a decline of -36.59%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 6.76% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.72.

Ocular Therapeutix Inc. [OCUL] – Who Are The Largest Shareholders?

In filings from Summer Road LLC, it is revealed that the company now owns 6,122,089 shares, or roughly 7.90% of the outstanding OCUL shares. Additionally, Opaleye Management, Inc. decreased -5.34% of its stake after which the total value it holdings stand at $26,241,200, while BlackRock Fund Advisors added 5.63% of its stake to hold $21.55 million in the firm. Over the last quarter, The Vanguard Group, Inc. sold -2,420 shares of Ocular Therapeutix Inc., while Millennium Management LLC sold 1,360,285 shares. At present, Deltec Asset Management LLC is holding 1,974,797 shares valued at $8.97 million. SSgA Funds Management, Inc. owned 1,576,213 shares of the company at the time of its most recent 13F filing, worth $7.16 million.

According to FactSet, Ocular Therapeutix Inc.’s share price will average $13.13 in the next year, based on opinions of analysts polled by the firm. This is up nearly 245.74 percent from its previous closing price of $3.76. Analysts expect Ocular Therapeutix Inc. stock to reach the higher price of $18.00, while the lowest price estimate is $9.00. However, 8 analysts have rated OCUL stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here